After a PhIII failure, the FDA delivers Blueprint an expected CRL

After a PhIII failure, the FDA delivers Blueprint an expected CRL

Source: 
Endpoints
snippet: 

Some CRLs come as little surprise.

This morning, the FDA rejected Blueprint Medicines’ application to have their cancer drug Ayvakit (avapritinib) approved for fourth-line gastrointestinal stromal tumors, or GIST. Already, though, in late April, the drug had failed the major test for that indication: A Phase III trial pitting Ayvakit against the already-approved Bayer GIST drug, regorafenib.